Browsing Tag
Eli Lilly and Company
178 posts
Lilly to expand into cardiovascular gene editing with Verve Therapeutics acquisition
Eli Lilly’s $1.3B acquisition of Verve Therapeutics targets breakthrough one-time gene therapies for high-risk cardiovascular patients. Read more.
Can Lilly’s flat $499/month Zepbound pricing reshape obesity drug access in the U.S.?
Lilly expands Zepbound access via LillyDirect, offering all FDA-approved doses for $499/month. Explore the implications for patients and the GLP-1 drug market.
The race for non-opioid pain relief: who’s leading the post-opioid era?
Explore the top companies and mechanisms leading the post-opioid pain relief revolution in 2025. Who's winning the race for safe, effective chronic pain drugs?
How Eli Lilly’s $1bn SiteOne deal strengthens its bid to lead in non-opioid pain therapies
Eli Lilly to acquire SiteOne Therapeutics for up to $1B, betting on STC-004 to redefine non-opioid pain treatment. Read why investors and analysts are watching.
Phase 3 trials to watch in 2025: Why this year matters for biotech investors
Explore the top Phase 3 trials of 2025 from Eli Lilly, GSK, and Innovent Biologics — including pipeline impact, investor sentiment, and regulatory milestones.
Eli Lilly strengthens ties with Purdue University to advance AI-powered drug discovery
Eli Lilly expands Purdue partnership with a $250M investment to drive AI-powered drug discovery, R&D scalability, and long-term pharma innovation.
Zepbound outperforms Wegovy in SURMOUNT-5 trial: Eli Lilly’s weight-loss drug achieves 47% greater relative reduction
Zepbound outperforms Wegovy with 20.2% weight loss in SURMOUNT-5 trial. See how Eli Lilly’s stock and investor sentiment responded to this clinical milestone.
Wall Street rout: Top U.S. stock losers on May 1 reflect deep-sector woes, policy shocks, and earnings misses
Discover how major U.S. companies like Eli Lilly and Becton Dickinson are navigating stock declines amid economic and industry challenges.
Lilly’s oral GLP-1 pill cuts blood sugar and weight without injections—Here’s what the breakthrough data shows
Lilly’s oral GLP-1 drug orforglipron showed strong A1C and weight loss results in Phase 3—find out how it could change diabetes care worldwide.
Top stock market trends – Eli Lilly jumps $105, Hertz explodes 44%, Trump Media rallies again
Explore why Hertz, Eli Lilly, and Trump Media led the top U.S. stock market gainers on April 17, 2025. Get key data, economic context, and investor insights now.